Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

Journal of Clinical Oncology

Volumn 24, Issue 1, 2006, Pages 25-35

  Faivre, Sandrine ^a   Delbaldo, Catherine ^a   Vera, Karina ^a   Robert, Caroline ^a   Lozahic, Stéphanie ^a   Lassau, Nathalie ^a   Bello, Carlo ^a   Deprimo, Samuel ^a   Brega, Nicoletta ^a   Massimini, Giorgio ^a   Armand, Jean Pierre ^a   Scigalla, Paul ^a   Raymond, Eric ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PYRROLE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG STRUCTURE; EDEMA; ESOPHAGITIS; FATIGUE; FEMALE; HAIR DISCOLORATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG EMBOLISM; MALE; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; PERIPHERAL EDEMA; PHLEBITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SKIN DISCOLORATION; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL; PIGMENTATION; SKIN;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; FEMALE; HUMANS; HYPERTENSION; INDOLES; MALE; MIDDLE AGED; NEOPLASMS; PIGMENTATION; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SKIN;

EID: 33644847440     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.2194     Document Type: Article

References (34)

1. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739, 2002
2. Ferrara N, Hillan KJ, Gerber HP, et al: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400, 2004
3. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
4. Yang JC, Haworth L, Sherry RM, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
5. Bergers G, Song S, Meyer-Morse N, et al: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295, 2003
6. Shaheen RM, Tseng WW, Davis DW, et al: Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 61:1464-1468, 2001
7. Ahmad T, Eisen T: Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10:6388S-6392S, 2004
8. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
9. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
10. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
11. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766, 2003
12. Abrams TJ, Murray LJ, Pesenti E, et al: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011-1021, 2003
13. Morimoto AM, Tan N, West K, et al: Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 23: 1618-1626, 2004
14. Yee KW, Schittenhelm M, O'Farrell AM, et al: Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3-ITD positive leukemic cells. Blood 104:4202-4209, 2004
15. Baratte S, Sarati S, Frigerio E, et al: Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr A 1024:87-94, 2004
16. O'Farrell AM, Foran JM, Fiedler W, et al: An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9:5465-5476, 2003
17. Fiedler W, Serve H, Donner H, et al: A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105:986-993, 2004
18. Rouffiac V, Bouquet C, Lassau N, et al: Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol 39:350-356, 2004
19. Robert C, Faivre S, Raymond E, et al: Subungual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 143:313-314, 2005
20. Osusky KL, Hallahan DE, Fu A, et al: The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effects on existing tumor vessels. Angiogenesis 7:225-233, 2004
21. Marx GM, Steer CB, Harper P, et al: Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock! J Clin Oncol 20:1446-1448, 2002
22. Kuenen BC, Levi M, Meijers JC, et al: Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 21:2192-2198, 2003
23. Kitamura R, Tsukamoto K, Harada K, et al: Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: Role of SCF/KIT protein interactions and the downstream effector, MITF-M. J Pathol 202:463-475, 2004
24. Hemesath TJ, Price ER, Takemoto C, et al: MAP kinase links the transcription factor Microphthalmia to c-Kit signaling in melanocytes. Nature 391:298-301, 1998
25. Botchkareva NV, Khlgatian M, Longley BJ, et al: SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 15:645-658, 2001
26. Tsao AS, Kantarjian H, Cortes J, et al: Imatinib mesylate causes hypopigmentation in the skin. Cancer 98:2483-2487, 2003
27. Etienne G, Cony-Makhoul P, Mahon FX: Imatinib mesylate and gray hair. N Engl J Med 347:446, 2002
28. Schueneman AJ, Himmelfarb E, Geng L, et al: Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 307:476-480, 2003
29. Robert C, Spatz A, Faivre S, et al: Tyrosine kinase inhibition and grey hair. Lancet 361:1056, 2003
30. Stroobants S, Goeminne J, Seegers M, et al: 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39:2012-2020, 2003
31. Demetri GD, George S, Heinrich MC, et al: Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol 22:814, 2003 (abstr 3273)
32. Toner GC, Mitchell PL, De Boer R, et al: PET imaging study of SU11248 in patients with advanced malignancies. Proc Am Soc Clin Oncol 22: 191, 2003 (abstr 767)
33. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
34. Demetri GD, Desai J, Fletcher JA, et al: SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 22:3001, 2004 (July 15 suppl)